Yvonne Greenstreet sold $12M of ALNY
Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC.. 25,650 shares at an average of $452.75, traded Nov 12, 2025, filed Nov 14, 2025.
Score components
- +25RoleCEO
- +25Trade size$11.6M at market
- +10Share of holdings soldSold 32% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.5%, 3m -30.0%, 6m -36.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000120, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 12, 2025 | MOption exercise Common Stock10b5-1 | +650 | $42.22 | $27k | 66,059 | Nov 14, 2025 |
| Nov 12, 2025 | MOption exercise Common Stock10b5-1 | +15,000 | $119.13 | $1.8M | 81,059 | Nov 14, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock10b5-1 | -711 | $448.07 | $319k | 80,348 | Nov 14, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock10b5-1 | -2,132 | $449.15 | $958k | 78,216 | Nov 14, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock10b5-1 | -453 | $450.17 | $204k | 77,763 | Nov 14, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock10b5-1 | -1,255 | $451.16 | $566k | 76,508 | Nov 14, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock10b5-1 | -1,210 | $452.43 | $547k | 75,298 | Nov 14, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock10b5-1 | -1,069 | $453.52 | $485k | 74,229 | Nov 14, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock10b5-1 | -1,960 | $454.84 | $891k | 72,269 | Nov 14, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock10b5-1 | -3,406 | $455.56 | $1.6M | 68,863 | Nov 14, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock10b5-1 | -2,420 | $456.64 | $1.1M | 66,443 | Nov 14, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock10b5-1 | -604 | $457.71 | $276k | 65,839 | Nov 14, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock10b5-1 | -430 | $458.42 | $197k | 65,409 | Nov 14, 2025 |
| Nov 13, 2025 | MOption exercise Common Stock10b5-1 | +10,000 | $119.13 | $1.2M | 75,409 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -654 | $447.73 | $293k | 74,755 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -1,013 | $448.76 | $455k | 73,742 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -1,477 | $450.02 | $665k | 72,265 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -2,218 | $450.69 | $1000k | 70,047 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -1,702 | $451.94 | $769k | 68,345 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -1,599 | $452.85 | $724k | 66,746 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -881 | $453.99 | $400k | 65,865 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -195 | $454.69 | $89k | 65,670 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock10b5-1 | -261 | $456.03 | $119k | 65,409 | Nov 14, 2025 |
| Nov 12, 2025 | MOption exercise Performance Stock Option 2016 (right to buy)derivative10b5-1 | -650 | $0.00 | $0 | 0 | Nov 14, 2025 |
| Nov 12, 2025 | MOption exercise Performance Stock Option 2017 (right to buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 10,000 | Nov 14, 2025 |
| Nov 13, 2025 | MOption exercise Performance Stock Option 2017 (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | Nov 14, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 25Weak | ALNYLAM PHARMACEUTICALS, INC. | David E I Pyott director | $1.1M 3,830 shares | -71% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Melissa McLaughlin Chief Human Resources Officer | $1.3M 3,910 shares | -29% | |
| 26Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $418k 1,291 shares | -6% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $746k 2,309 shares | -6% | |
| 59Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $797k 2,468 shares | -4% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $948k 2,933 shares | -3% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.5M 4,713 shares | -20% | |
| 65Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $2.2M 6,799 shares | -6% | |
| 48Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $524k 1,598 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.